AXL in myeloid malignancies – an elusive target?

Pia Aehnlich, Katharina Leuchte*, Claudia Schöllkopf, Sara Fresnillo Salo, Tina J. Seremet, Estrid Høgdall, Özcan Met, Kirsten Grønbaek, Per thor Straten

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

1 Downloads (Pure)

Abstract

The TAM receptor tyrosine kinase family member AXL plays critical roles in tissue homeostasis, survival, chemoresistance, and motility. This study investigates the receptor expression in six AML cell lines and bone marrow myeloblasts from 25 patients with myeloid neoplasms. We found that AXL expression was generally absent or very low in AML myeloblasts. These findings suggest that the efficacy of AXL inhibitors may not depend on AXL positivity but rather on alternative therapeutic mechanisms, such as inducing significant immune responses.
OriginalsprogEngelsk
Artikelnummer158
TidsskriftBiomarker Research
Vol/bind12
Udgave nummer1
Antal sider5
ISSN2050-7771
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
This work was funded by the following grants: Danish Council for Independent Research (Grant No. DFF-1331-00095B), Danish Cancer Society (Grant No. R72-A4396-13-S2), The Danielsen Foundation, Dagmar Marshalls Fond, Else og Mogens Wedell-Wedellsborg Fond, AP M\u00F8ller Fonden, Den B\u00F8hmske Fond, KV foundation, Familien Erichsens Mindefond (all to PtS), PA received a partial PhD stipend from the Clinical Academic Group in Translational Hematology, part of Greater Copenhagen Health Science Partners, and likewise a partial PhD stipend from Dept. of Immunology and Microbiology, University of Copenhagen.

Publisher Copyright:
© The Author(s) 2024.

Citationsformater